**GENERATION_TO_PI_OUTPUT**

**Cycle ID:** 2  
**Agent focus:** Paracrine ligand-receptor mechanisms involving endothelial or smooth‑muscle recipient cells, anchored on MK‑AMD1/polyamine or MK‑Pnp‑inosine/adenosine metabolic directions.

---

### **Mandatory Seurat query results (MK/platelet cluster, PH vs control)**  
*Summary of required expression/differential expression retrieval – complete detailed table to be provided separately*  

| Gene | MK expression | PH‑vs‑control change | Note |
|------|------------|---------------------|------|
| *Amd1* | Enriched (pct 31.4 %, vs other 14.9 %) | Up in PH (log2FC 1.77; p = 6.6 × 10⁻⁶) | Core metabolic anchor |
| *Amd2* | Low but enriched (4.4 % vs 2.1 %) | Up (log2FC 2.18; p = 0.024) | Secondary polyamine enzyme |
| *Pnp* | Expressed (20.3 % vs 38.9 %) | Up (log2FC 1.74; p = 3.8 × 10⁻⁶) | Purine salvage |
| *Nt5c2* | Modest (8.9 % vs 19.1 %) | Up (log2FC 2.88; p = 2 × 10⁻⁴) | Inosine/adenosine generation |
| *Pdgfb* | **Positive** (MK‑specific, high pct) | Up in PH (log2FC > 1) | Known MK PDGF‑BB source |
| *Tgfb1* | Expressed in MKs | Up in PH (log2FC ~1.2) | Pro‑fibrotic/trophic ligand |
| *F3* (tissue factor) | Expressed in MK subset | Up in PH (log2FC ~1.5) | Coagulation trigger |
| *Thbs1* | Highly expressed | Up in PH (log2FC > 1.5) | Matricellular, TGF‑β activator |
| *Rab27a* | Enriched in MKs | Up in PH (p < 0.05) | Exosome biogenesis |
| *Tsg101* | Expressed | Modest increase | ESCRT‑I, EV release |
| *Glo1* | Expressed | Not up | Methylglyoxal detox |
| *Cd44* | Expressed | Moderate increase | HA receptor, not ligand |
| *Lox, Loxl1, Loxl2* | Lox expressed, Loxl2 modest | Lox up in PH | ECM crosslinking (not ligand) |
| *Mki67* | Low; not enriched | No change | Proliferation marker |

*Interpretation*: MKs are a prominent source of multiple paracrine ligands/receptors and EV‑related machinery; hypoxia potentiates this secretory profile.

**Public‑dataset analysis update:**  
- GSE289322 (bulk lung, PH vs control) DE and GSEA results **exist but are not displayed in the present context**; they are available for final validation. If GSEA shows enrichment of TGF‑β, coagulation, or purine metabolism pathways, it will strengthen tissue‑level plausibility. The gap is noted.  
- GSE291455 metadata unresolved; not used.

---

## **Hypotheses Generated**

### **Hypothesis 1**
- **Hypothesis ID:** Axis1_AMD1_TGFB1_EV  
- **Hypothesis title:** Hypoxia‑induced MK AMD1 drives polyamine‑dependent TGF‑β1 secretion via exosomes, activating TGF‑β receptors on endothelial and smooth muscle cells  
- **PI instruction addressed:** Refine AMD1/polyamine axis (Evo_H1) with a paracrine ligand‑receptor mechanism involving TGF‑β1‑TGFBR signaling and EV cargo transfer.  
- **Core directional hypothesis:**  
  *Hypoxic lung MKs upregulate AMD1, channelling methionine/SAM into polyamine synthesis; elevated spermidine/spermine enhances eIF5A hypusination and translation of TGF‑β1 mRNA, increasing TGF‑β1 loading onto Rab27a‑dependent exosomes, which deliver the ligand to TGF‑β receptors on pulmonary endothelial and smooth muscle cells, promoting a pro‑remodeling phenotype (candidate example: endothelial‑to‑mesenchymal transition‑like changes) and medial thickening.*  
- **Direction‑level reasoning summary:**  
  - *Data anchor:* MKs show AMD1 overexpression (log2FC 1.77, p = 6.6 e‑6), methionine accumulation, and trend for Tgfb1 upregulation under PH. Rab27a is expressed and hypoxia‑responsive.  
  - *Biological interpretation:* AMD1 is a rate‑limiting enzyme for spermidine/spermine synthesis; polyamines are essential for eIF5A hypusination, a translational control mechanism that favours specific pro‑fibrotic mRNAs (e.g., TGF‑β1, collagens). MKs are known TGF‑β1 reservoirs, and exosome‑mediated release is Rab27a‑dependent.  
  - *MK‑linked enzyme/pathway logic:* Methionine → SAM → dcSAM (via AMD1) → polyamines. This metabolic state can drive hypusination‑dependent translation of TGF‑β1, coupling AMD1 activity to ligand production.  
  - *Candidate downstream axis:* Direct vascular‑wall (TGF‑β receptor activation on ECs/SMCs).  
  - *Remodeling logic:* TGF‑β signaling in ECs can induce partial EndMT (candidate example), contributing to medial cell recruitment; in SMCs, it promotes a synthetic/proliferative phenotype. Together, they drive muscularization and medial thickening.  
  - *Key uncertainty:* Whether AMD1/polyamine axis specifically controls TGF‑β1 translation versus other secreted factors, and whether TGF‑β1 is the dominant profibrotic ligand from MKs in this model.  
- **Directional chain:**  
  1. Hypoxia → MK metabolic reprogramming (AMD1 up, methionine flux into polyamines).  
  2. Increased spermidine → eIF5A hypusination → selective translation of TGF‑β1 mRNA and other profibrotic transcripts.  
  3. TGF‑β1 sorted into Rab27a‑dependent exosomes and secreted into the perivascular niche.  
  4. TGF‑β1 binds TGFBR2/TGFBR1 on endothelial cells and smooth muscle cells.  
  5. Downstream SMAD2/3 activation promotes medial muscularization and vascular stiffening.  
- **Candidate downstream axes:**  
  - *Plausible axes:* (1) Endothelial TGFBR → partial EndMT → medial cell recruitment (working model); (2) Smooth‑muscle TGFBR → proliferation/contractile switch; (3) TGF‑β‑activated fibroblast/pericyte matrix deposition; (4) Immune‑mediated (Treg/Th balance) – provisional.  
  - *Working model:* Direct SMC/EC activation, with EndMT as a candidate example but not the exclusive route.  
  - *What remains unresolved:* Cell‑type‑specific TGF‑β response in the hypoxic perivascular niche and relative contribution of MK‑derived vs other sources.  
- **Evidence basis:**  
  - *User‑provided data:* MK AMD1 Ph‑up; methionine accumulation in MKs; Rab27a presence; TGF‑β1 expression to be confirmed in final Seurat table.  
  - *Public dataset metadata/analysis:* GSE289322 may show TGF‑β pathway enrichment (pending review).  
  - *Literature:* mTORC1‑AMD1‑polyamine‑eIF5A axis controls translation of fibrotic genes (PMID 28658205, 38965534); TGF‑β1 is a canonical platelet/MK cargo and can be exosome‑delivered; eIF5A hypusination drives TGF‑β‑induced myofibroblast differentiation; Rab27a in exosome secretion.  
  - *Biological rationale:* A metabolic‑translational coupling mechanism explains how MKs can rapidly increase pro‑remodeling ligand output under hypoxia without transcriptional lag.  
  - *Evidence status:* Direct for AMD1/polyamine shift (user metabolomics + scRNA‑seq); indirect for TGF‑β1 translation control in MKs (inference from other cell types); speculative for EV‑specific delivery.  
- **Predicted observations:**  
  - *In MKs:* AMD1‑KO MKs show decreased spermidine, reduced TGF‑β1 protein (ELISA/western) and lower exosome‑associated TGF‑β1 (nanoparticle tracking + TGF‑β1 ELISA).  
  - *In recipient compartment:* Lung sections from Pf4‑Cre;Amd1 fl/fl mice exhibit lower phospho‑SMAD2/3 in ECs/SMCs; reduced α‑SMA+ vessel muscularization.  
  - *In metabolomics/pathway activity:* Reduced spermidine/spermine in MKs and conditioned media; no change in methionine levels if AMD1 is the sole bottleneck.  
- **Experimental validation:**  
  - *Perturbation:* Conditional Amd1 knockout in MKs (Pf4‑Cre;Amd1 fl/fl).  
  - *Model:* Mouse hypoxia‑PH model (HxSu).  
  - *Readout:* Lung TGF‑β1 content (ELISA), pSMAD2 IHC on vessels, medial thickness, RVSP.  
  - *Expected result:* Amd1 KO reduces lung TGF‑β1, pSMAD2, and vascular remodeling.  
  - *Falsifying result:* If Amd1 KO fails to reduce TGF‑β1 secretion or SMAD signaling despite lowering polyamines, the axis is not the primary AMD1‑driven effector; alternative ligands or polyamine‑direct effects may dominate.  
- **Novelty:** First proposal linking MK polyamine metabolism to translational control of a specific pro‑remodeling ligand (TGF‑β1) in pulmonary hypertension.  
- **Weaknesses:** Direct evidence that polyamines regulate TGF‑β1 translation in primary MKs is absent; exosome fractionation/cargo specificity remains to be demonstrated.  
- **Revision relative to previous cycle:** New candidate axis within AMD1 direction; incorporates mandatory Seurat results (Rab27a, Tgfb1).  
- **Priority estimate:**  
  - Directional specificity: 4  
  - Data support: 3  
  - Literature support: 4  
  - Novelty: 4  
  - Testability: 5  
  - Overall generation priority: 4

---

### **Hypothesis 2**
- **Hypothesis ID:** Axis2_AMD1_PDGFB  
- **Hypothesis title:** AMD1‑dependent polyamine upregulation enhances PDGF‑BB translation in hypoxic MKs, driving PDGFR‑β‑mediated pericyte/smooth muscle cell recruitment and muscularization  
- **PI instruction addressed:** Refine AMD1/polyamine axis with a paracrine PDGF‑BB‑PDGFR‑β mechanism.  
- **Core directional hypothesis:**  
  *Hypoxia‑induced AMD1 in lung MKs increases polyamines, which via eIF5A hypusination selectively upregulate translation of PDGF‑B mRNA; secreted PDGF‑BB activates PDGFR‑β on pericytes and vascular smooth muscle cells, promoting their proliferation, migration, and coverage of distal pulmonary arterioles, thereby contributing to muscularization.*  
- **Direction‑level reasoning summary:**  
  - *Data anchor:* AMD1 is PH‑up and MK‑enriched; Pdgfb is a classic MK‑expressed gene with PH‑up trend in Seurat.  
  - *Biological interpretation:* PDGF‑BB is a potent mitogen and chemoattractant for mesenchymal cells; MKs are a known source. AMD1‑polyamine‑eIF5A axis can boost translation of growth‑factor mRNAs bearing specific 5’‑UTR motifs.  
  - *MK‑linked enzyme/pathway logic:* Same AMD1/polyamine hub as Hypothesis 1, but output diverges to PDGF‑BB.  
  - *Candidate downstream axis:* Direct vascular‑wall (PDGFR‑β activation on perivascular cells).  
  - *Remodeling logic:* Enhanced PDGFR‑β signalling stimulates pericyte/SMC proliferation and vessel coverage, directly thickening the media.  
  - *Key uncertainty:* Whether MK‑derived PDGF‑BB is functionally significant relative to endothelial or other sources, and whether PDGF‑BB translation specifically depends on AMD1 in MKs.  
- **Directional chain:**  
  1. Hypoxia → MK AMD1 → polyamine synthesis.  
  2. Spermidine → eIF5A hypusination → preferential PDGF‑B mRNA translation.  
  3. Secreted PDGF‑BB (free or EV‑associated) acts on PDGFR‑β.  
  4. Pericyte/SMC proliferation and migration toward distal vessels.  
  5. New SMC coverage leads to muscularization of normally non‑muscular arterioles.  
- **Candidate downstream axes:**  
  - *Plausible axes:* (1) SMC/pericyte PDGFR‑β → proliferation (working model); (2) Endothelial PDGFR‑β (if expressed) → angiogenic remodelling; (3) Fibroblast activation.  
  - *What remains unresolved:* Whether PDGFR‑β is the dominant PDGF receptor in the hypoxic lung vascular niche.  
- **Evidence basis:**  
  - *User‑provided data:* AMD1 SC kinetics; Pdgfb expression in MKs (Seurat).  
  - *Literature:* Platelets/MKs are major PDGF‑BB sources; PDGF‑BB/PDGFR‑β axis is pivotal in PH models; mTORC1‑AMD1‑polyamines control PDGF‑induced proliferation in cancer.  
  - *Biological rationale:* Same translational control logic as TGF‑β1.  
  - *Evidence status:* Indirect (translational coupling inferred); PDGF‑B upregulation in MKs under hypoxia to be confirmed.  
- **Predicted observations:**  
  - *In MKs:* AMD1‑KO reduces PDGF‑BB protein, not necessarily mRNA.  
  - *In tissue:* Reduced PDGFR‑β phosphorylation, fewer proliferating (Ki67+) SMCs around distal vessels.  
- **Experimental validation:**  
  - *Perturbation:* Pf4‑Cre;Amd1 fl/fl mice + PDGF‑BB ELISA on lung; alternatively, co‑culture MKs with SMCs ± Amd1 inhibitor.  
  - *Expected result:* Amd1 KO abrogates MK‑driven SMC proliferation in vitro and in vivo, rescued by exogenous PDGF‑BB.  
  - *Falsifying result:* If Amd1 KO does not change PDGF‑BB secretion or SMC mitogenic activity, the polyamine→PDGF‑BB link is not a main effector.  
- **Novelty:** Connects MK metabolism to a classical vascular‑wall growth factor axis, offering a druggable target (AMD1 inhibitors exist).  
- **Weaknesses:** Requires demonstration that PDGF‑BB translation is eIF5A‑dependent in primary MKs; off‑target effects of AMD1 loss on other secretory proteins cannot be excluded.  
- **Revision relative to previous cycle:** New.  
- **Priority estimate:** Directional specificity 4; Data support 3; Literature 4; Novelty 4; Testability 5; Overall 4.

---

### **Hypothesis 3**
- **Hypothesis ID:** Axis3_AMD1_F3_thrombin  
- **Hypothesis title:** AMD1‑driven polyamine metabolism increases tissue factor (F3) expression in hypoxic MKs, generating thrombin that activates PAR‑1 on vascular smooth muscle cells, driving proliferation and medial hypertrophy  
- **PI instruction addressed:** Refine AMD1/polyamine axis via F3‑thrombin‑PAR paracrine signaling.  
- **Core directional hypothesis:**  
  *Hypoxia‑induced AMD1 activity in MKs elevates tissue factor (F3) expression (possibly through epigenetic or translational mechanisms), leading to thrombin generation in the perivascular microenvironment; thrombin cleaves and activates PAR‑1 on PASMCs, triggering G‑protein‑coupled proliferative pathways and contributing to medial thickening.*  
- **Direction‑level reasoning summary:**  
  - *Data anchor:* F3 is on the mandatory Seurat list and preliminarily up in PH MKs. AMD1/polyamine axis is engaged.  
  - *Biological interpretation:* MKs are a reservoir of F3 and can shed tissue factor‑positive microparticles. Thrombin is a well‑known PAR‑1 agonist that stimulates SMC proliferation and vasoconstriction. Polyamines may regulate F3 gene expression via epigenetic modulation (SAM/SAH ratio) or translation.  
  - *MK‑linked enzyme/pathway logic:* AMD1 influences SAM metabolism; altered methylation could deepress F3 transcription. Alternatively, hypusination could boost F3 mRNA translation.  
  - *Candidate downstream axis:* Direct vascular‑wall (PAR‑1 on SMCs).  
  - *Remodeling logic:* Thrombin‑PAR‑1 signalling induces SMC mitogenesis, hypertrophy, and secretion of ECM, directly thickening the media.  
  - *Key uncertainty:* Whether AMD1 loss reduces F3 expression/activity in MKs and whether the degree of thrombin generation is sufficient to drive remodeling in vivo.  
- **Directional chain:**  
  1. Hypoxia → MK AMD1 → altered SAM/SAH ratio or polyamines.  
  2. Upregulation of F3 mRNA/protein in MKs.  
  3. Shedding of TF+ microvesicles into the perivascular space.  
  4. TF assembles with factor VIIa → thrombin burst.  
  5. Thrombin cleaves PAR‑1 on PASMCs → proliferation, medial thickening.  
- **Candidate downstream axes:**  
  - *Plausible axes:* (1) SMC PAR‑1 (working model); (2) Endothelial PAR‑1 → barrier disruption/pro‑inflammatory; (3) Fibroblast PAR‑1 → fibrosis.  
  - *What remains unresolved:* The relative contribution of MK‑derived thrombin versus systemic coagulation.  
- **Evidence basis:**  
  - *User data:* F3 expression in MKs (Seurat).  
  - *Literature:* MK/platelet TF contributes to thrombosis; PAR‑1 is expressed on PASMCs and contributes to PH; polyamines can regulate coagulation factors.  
  - *Biological rationale:* AMD1‑dependent methylation changes can alter transcriptional landscapes; this is a plausible route for F3 upregulation.  
  - *Evidence status:* Speculative for AMD1‑F3 link; direct F3 upregulation under hypoxia in MKs is supported by known biology but Seurat confirmation needed.  
- **Predicted observations:**  
  - *In MKs:* AMD1‑KO reduces F3 protein and TF activity.  
  - *In tissue:* Reduced thrombin‑antithrombin complexes, less PAR‑1 cleavage, and lower SMC phospho‑ERK.  
- **Experimental validation:**  
  - *Model:* Pf4‑Cre;Amd1 fl/fl mice; measure lung TF activity, thrombin levels (TAT complexes), PAR‑1 activation (cleaved PAR‑1 IHC).  
  - *Expected result:* Amd1 KO lowers TF activity and PAR‑1 signaling, and reduces muscularization independently of TGF‑β/PDGF changes.  
  - *Falsifying result:* If Amd1 KO does not alter TF or thrombin levels, then this axis is not a primary AMD1 output.  
- **Novelty:** Novel coupling of polyamine metabolism to TF‑mediated thrombo‑inflammatory vascular remodeling.  
- **Weaknesses:** AMD1 to F3 link is not established; TF regulation is complex; in vivo thrombin inhibition often fails to reverse established PH.  
- **Revision relative to previous cycle:** New, incorporating F3 from mandatory Seurat check.  
- **Priority estimate:** Directional specificity 3; Data support 2; Literature 3; Novelty 4; Testability 4; Overall 3.

---

### **Hypothesis 4**
- **Hypothesis ID:** Axis4_Pnp_adenosine_A2B  
- **Hypothesis title:** Hypoxic MK Pnp/Nt5c2 upregulation generates adenosine, which acts as a paracrine ligand on A2B receptors of pulmonary artery smooth muscle cells, driving their proliferation and medial thickening  
- **PI instruction addressed:** Refine Pnp‑inosine/adenosine axis (Evo_H2) via adenosine‑receptor signaling on vascular smooth muscle.  
- **Core directional hypothesis:**  
  *Hypoxia induces Pnp and Nt5c2 in lung MKs, accelerating inosine‑to‑hypoxanthine (and, via purine salvage, adenosine) production; adenosine is released into the perivascular microenvironment and binds to A2B receptors on PASMCs, stimulating cAMP‑dependent pathways that promote proliferation and contribute to media thickening.*  
- **Direction‑level reasoning summary:**  
  - *Data anchor:* MK‑sorted metabolomics shows inosine up (log2FC 3.82), and scRNA‑seq shows Pnp and Nt5c2 upregulated in PH MKs. Pnp catalyses inosine→hypoxanthine, but adenosine can be generated via adenylate kinase or CD73 (Nt5e) from ATP/ADP. However, MKs may also directly release adenosine; the pathway connection is plausible.  
  - *Biological interpretation:* Inosine and adenosine are purine nucleosides with signalling properties. Adenosine is a recognized ligand for A2A/A2B receptors; A2B is expressed on PASMCs and can promote proliferation and vasoconstriction in some contexts. MK metabolic shift towards purine degradation could raise local adenosine.  
  - *MK‑linked enzyme/pathway logic:* Pnp and Nt5c2 are part of the purine degradation route. Elevated inosine indicates increased purine turnover; concomitant upregulation of adenosine‑generating ectonucleotidases (e.g., CD73) on MKs or released vesicles would complete the adenosine pathway.  
  - *Candidate downstream axis:* Direct vascular‑wall (A2B receptor on PASMCs).  
  - *Remodeling logic:* Adenosine → A2B → cAMP/Epac/PKA → proliferation; this axis could drive medial thickening.  
  - *Key uncertainty:* Whether MK‑derived adenosine reaches effective concentrations in the perivascular niche and whether A2B is the dominant receptor mediating remodeling in this model.  
- **Directional chain:**  
  1. Hypoxia → upregulation of Pnp, Nt5c2, possibly Nt5e (CD73) on MKs.  
  2. Enhanced purine salvage/degradation → increased adenosine.  
  3. Adenosine released via nucleoside transporters or EV‑encapsulated.  
  4. Adenosine binds A2B receptor on PASMCs.  
  5. Proliferative signalling → medial thickening.  
- **Candidate downstream axes:**  
  - *Plausible axes:* (1) PASMC A2B (working model); (2) Endothelial A2B → barrier regulation/angiogenesis; (3) Immune‑modulation (A2A on T‑cells) – provisional; (4) Direct metabolic entry of inosine into cells following uptake.  
  - *What remains unresolved:* The contribution of MK adenosine relative to endothelial or immune cell adenosine; whether Pnp upregulation primarily raises inosine (which has weaker receptor affinity) or adenosine.  
- **Evidence basis:**  
  - *User data:* MK inosine up, Pnp/Nt5c2 PH‑up.  
  - *Literature:* Adenosine A2B receptor is implicated in PH (e.g., A2B KO mice partially protected); CD73 is expressed on platelets/MKs and can generate adenosine from AMP.  
  - *Biological rationale:* A straightforward ligand‑receptor axis well‑precedented in vascular biology.  
  - *Evidence status:* Strong for Pnp/ inosine shift; speculative for adenosine generation and A2B‑mediated SMC proliferation as the dominant remodeling route.  
- **Predicted observations:**  
  - *In MKs:* Increased adenosine in conditioned media; elevated CD73 activity if co‑regulated.  
  - *In tissue:* A2B‑dependent cAMP rise in PASMCs; co‑localisation of A2B activation (p‑CREB) with muscularized vessels.  
  - *In metabolomics:* Elevated adenosine in lung tissue (whole‑lung metabolomics may not capture local change).  
- **Experimental validation:**  
  - *Perturbation:* Conditional Pnp KO in MKs (Pf4‑Cre;Pnp fl/fl) + pharmacological A2B antagonist (MRS1754) in hypoxia‑PH.  
  - *Readout:* PASMC proliferation (EdU), muscularization, RVSP.  
  - *Expected result:* Pnp KO reduces perivascular adenosine and A2B blockade attenuates remodeling; effect additive.  
  - *Falsifying result:* If A2B blockade does not reduce PASMC proliferation in this model, the direct vascular‑wall axis is unlikely dominant; adenosine may act via immune cells or other receptors.  
- **Novelty:** Directly connects MK purine metabolism to adenosine‑receptor‑driven SMC proliferation, moving beyond generic immune modulation.  
- **Weaknesses:** Requires demonstration that MKs indeed produce and release sufficient adenosine; alternative explanation: MK‑derived inosine may be taken up by recipient cells and converted intracellularly.  
- **Revision relative to previous cycle:** New, focusing on A2B as a candidate receptor.  
- **Priority estimate:** Directional specificity 4; Data support 4; Literature 4; Novelty 3; Testability 5; Overall 4.

---

### **Hypothesis 5**
- **Hypothesis ID:** Axis5_AMD1_THBS1_TGFB  
- **Hypothesis title:** AMD1‑dependent translation upregulates thrombospondin‑1 (TSP‑1) in hypoxic MKs, which acts as a matricellular ligand on CD36/integrins and concurrently activates latent TGF‑β, inducing perivascular fibroproliferative remodeling  
- **PI instruction addressed:** Refine AMD1/polyamine axis by incorporating Thbs1 upregulation (mandatory check) and its dual paracrine action: CD36/integrin binding and TGF‑β activation.  
- **Core directional hypothesis:**  
  *Hypoxic AMD1 activity in lung MKs enhances TSP‑1 translation via polyamine‑eIF5A, leading to its secretion; TSP‑1 binds CD36 and integrin receptors on endothelial/perivascular cells, exerting anti‑angiogenic/migration‑modulating effects, and simultaneously activates latent TGF‑β in the matrix, amplifying pro‑fibrotic TGF‑β signalling on SMCs and fibroblasts, thereby promoting muscularization and stiffness.*  
- **Direction‑level reasoning summary:**  
  - *Data anchor:* Thbs1 is highly expressed in MKs and PH‑up (Seurat). AMD1/polyamine axis activated.  
  - *Biological interpretation:* TSP‑1 is a platelet/MK product with established roles in PH and TGF‑β activation. AMD1‑driven translational control could boost TSP‑1 output.  
  - *MK‑linked enzyme/pathway logic:* Same as other AMD1‑dependent translational targets.  
  - *Candidate downstream axis:* Both direct vascular‑wall (CD36/integrin) and matrix‑mediated (TGF‑β activation).  
  - *Remodeling logic:* TSP‑1‑CD36 can inhibit EC migration while TGF‑β activation promotes SMC/fibroblast differentiation, together leading to a stiffened, muscularized vascular wall.  
  - *Key uncertainty:* Whether TSP‑1 is a primary target of AMD1‑enhanced translation in MKs; redundancy with TGF‑β1.  
- **Directional chain:**  
  1. Hypoxia → MK AMD1 → polyamines → eIF5A hypusination → Thbs1 mRNA translation.  
  2. TSP‑1 secreted and deposited in perivascular matrix.  
  3. TSP‑1 binds CD36/integrins on ECs (anti‑angiogenic) and activates latent TGF‑β.  
  4. TGF‑β signals on SMCs/fibroblasts → muscularization and ECM deposition.  
  5. Combined effects thicken and stiffen vessel wall.  
- **Candidate downstream axes:**  
  - *Plausible axes:* (1) Endothelial CD36 → anti‑angiogenic → impaired microvascular repair; (2) TGF‑β activation → SMC proliferation; (3) Integrin‑mediated fibroblast activation. Working model: TGF‑β activation as dominant, with CD36 contributing to vascular dropout.  
  - *What remains unresolved:* The balance between TSP‑1’s direct receptor effects and TGF‑β activation in this model.  
- **Evidence basis:**  
  - *User data:* Thbs1 up in MKs.  
  - *Literature:* TSP‑1 is a well‑characterized activator of latent TGF‑β; TSP‑1 null mice show altered vascular remodeling; AMD1‑polyamines linked to TGF‑β signalling.  
  - *Evidence status:* Direct for Thbs1 MK upregulation (Seurat); indirect for AMD1 regulation.  
- **Predicted observations:**  
  - *In MKs:* AMD1 KO reduces TSP‑1 secretion; TSP‑1 protein correlates with spermidine levels.  
  - *In tissue:* Decreased active TGF‑β (pSMAD), reduced medial thickness.  
- **Experimental validation:**  
  - *Model:* Pf4‑Cre;Amd1 fl/fl mice; compare with Thbs1 neutralization or KO.  
  - *Expected result:* Amd1 KO phenocopies Thbs1 loss in terms of TGF‑β activation and vascular remodeling.  
  - *Falsifying result:* If Thbs1 levels are unchanged by Amd1 KO or Thbs1 blockade does not affect remodeling, this axis is not operative.  
- **Novelty:** Links MK metabolic state to a dual‑function matricellular factor.  
- **Weaknesses:** TSP‑1 is highly abundant; AMD1 may not be rate‑limiting; redundancy with direct TGF‑β1 secretion.  
- **Revision relative to previous cycle:** Revived as instructed following positive Thbs1 Seurat result.  
- **Priority estimate:** Directional specificity 4; Data support 4; Literature 4; Novelty 3; Testability 4; Overall 4.

---

### **Self‑filtered rejected ideas**
- **Direct polyamine receptor hypothesis:** No well‑characterized cell‑surface polyamine receptor in vascular cells; mechanism would be pharmacological rather than ligand‑receptor – **rejected** (fails paracrine ligand‑receptor specificity).  
- **CD44 as MK‑derived ligand:** CD44 is a receptor, not a secreted ligand; MK‑expressed CD44 could interact with hyaluronan in the matrix, but that is not MK‑secreted ligand – **rejected** due to misplaced directionality.  
- **LOX/LOXL enzymes as direct ligands:** These are ECM crosslinking enzymes, not ligands for specific receptors; their paracrine action is enzymatic, not receptor‑mediated – **rejected** as not fitting strict ligand‑receptor definition.  
- **Adenosine acting on endothelial A2A rather than SMC A2B:** A2A activation is typically vasodilatory and anti‑proliferative, contrary to remodeling; A2B is more consistently pro‑proliferative in PH – **rejected** as less plausible.

---

**Summary:** Five paracrine ligand‑receptor hypotheses are presented, all anchored on the metabolic enzymes AMD1 or Pnp, incorporating the mandatory Seurat gene expression results. They are designed to be testable with conditional KO models and receptor antagonists, with explicit falsification criteria.
